pramlintide + insulin glargine

The combination of **pramlintide + insulin glargine** involves co-administration of two injectable antidiabetic agents. **Pramlintide** is a synthetic analogue of human amylin, a hormone co-secreted with insulin by pancreatic beta cells, which works by delaying gastric emptying, suppressing inappropriate postprandial glucagon secretion, and increasing satiety, thus lowering postprandial glucose excursions[5][7]. **Insulin glargine** is a long-acting recombinant human insulin analogue that provides a steady basal insulin level to regulate fasting plasma glucose[4][6]. This combination is used in patients with type 2 diabetes (and in some cases type 1) who are suboptimally controlled on basal insulin therapy alone. Clinical studies show that adding pramlintide to insulin glargine improves glycemic control (lowering A1C and postprandial glucose), reduces body weight, and does not increase the incidence of severe hypoglycemia with careful monitoring and insulin dose adjustment[1][3]. Pramlintide and insulin glargine must be administered as separate injections and should not be mixed due to incompatibility[5].

Other names

amylin analogue + insulin glargineamylinomimetic + long-acting insulinprAMLINTIDE acetate + insulin glargine